Hi @dachopper,
re your comment " Because... Adult Gvhd is 5 times the number of patients than pediatric", I think you'll find it's even better than that.
The exact quote from CEO Itescu (Feb 28, 2024 Earnings Call) was:
" For adult steroid-refractory acute GVHD, we are collaborating ... to conduct a pivotal trial in adults with this condition in patients who have failed second-line therapies and have no approved therapeutics. This potential market is 5x larger than for pediatric. " (underlining added for emphasis)
and again:
" For adults, adolescents and adults over the age of 12, ruxolitinib is the only approved therapy. And 45% of those who receive ruxolitinib are nonresponders. For the nonresponders, there are no approved therapies."
In other words, it is the adult Ruxolitinib 'non-responder' market ALONE which is 5 x larger than the market for the paediatric indication i.e. those sometimes characterised as RR-aGVHD.
A significant & yet unestimated part of the adult market for SR - aGVHD treatments may 'respond' to Ruxolitinib, and yet attending physicicans may have reservations or outright concerns/ fears about prescribing Ruxolitinib as treatment given it's undeniable toxicity, adverse event profile & Novartis/ Incyte's squirrely behaviour when it comes to producing long-term overall survival i.e. mortality/ morbidity data.
I think we'll find the paradigm shift will generate its own momentum & there will be little need to promote RYONCIL for off-label use.
Cheers
GLTA(LT)H
- Forums
- ASX - By Stock
- MSB
- 2024 Here we go again.
2024 Here we go again., page-496
-
- There are more pages in this discussion • 271 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online